EFG Asset Management Americas Corp. lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.8% during the third quarter, Holdings Channel.com reports. The firm owned 19,137 shares of the medical research company’s stock after purchasing an additional 332 shares during the period. Thermo Fisher Scientific accounts for 1.7% of EFG Asset Management Americas Corp.’s holdings, making the stock its 16th biggest position. EFG Asset Management Americas Corp.’s holdings in Thermo Fisher Scientific were worth $5,574,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the company. Putnam FL Investment Management Co. raised its position in shares of Thermo Fisher Scientific by 2.5% during the third quarter. Putnam FL Investment Management Co. now owns 41,962 shares of the medical research company’s stock worth $12,222,000 after purchasing an additional 1,031 shares during the period. Foster Dykema Cabot & Co. Inc. MA raised its position in shares of Thermo Fisher Scientific by 2.8% during the third quarter. Foster Dykema Cabot & Co. Inc. MA now owns 34,319 shares of the medical research company’s stock worth $9,996,000 after purchasing an additional 919 shares during the period. BBVA USA Bancshares Inc. raised its position in shares of Thermo Fisher Scientific by 8.5% during the third quarter. BBVA USA Bancshares Inc. now owns 31,488 shares of the medical research company’s stock worth $9,172,000 after purchasing an additional 2,463 shares during the period. Wellington Shields Capital Management LLC raised its position in shares of Thermo Fisher Scientific by 5.2% during the third quarter. Wellington Shields Capital Management LLC now owns 18,325 shares of the medical research company’s stock worth $5,338,000 after purchasing an additional 900 shares during the period. Finally, Groesbeck Investment Management Corp NJ raised its position in shares of Thermo Fisher Scientific by 3.5% during the third quarter. Groesbeck Investment Management Corp NJ now owns 3,390 shares of the medical research company’s stock worth $987,000 after purchasing an additional 115 shares during the period. 88.06% of the stock is currently owned by institutional investors.

TMO has been the subject of a number of analyst reports. Needham & Company LLC increased their price target on Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. ValuEngine lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Robert W. Baird increased their price target on Thermo Fisher Scientific from $305.00 to $319.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. Credit Suisse Group reissued a “buy” rating and issued a $310.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday, July 31st. Finally, JPMorgan Chase & Co. increased their price target on Thermo Fisher Scientific from $315.00 to $330.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $314.45.

NYSE TMO opened at $293.53 on Tuesday. The firm has a market capitalization of $118.15 billion, a P/E ratio of 26.40, a PEG ratio of 1.91 and a beta of 1.14. The business has a fifty day simple moving average of $290.07 and a 200 day simple moving average of $283.92. Thermo Fisher Scientific Inc. has a 12 month low of $208.34 and a 12 month high of $306.00. The company has a current ratio of 1.80, a quick ratio of 1.23 and a debt-to-equity ratio of 0.56.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $2.94 EPS for the quarter, beating analysts’ consensus estimates of $2.88 by $0.06. The business had revenue of $6.27 billion during the quarter, compared to analyst estimates of $6.19 billion. Thermo Fisher Scientific had a return on equity of 17.16% and a net margin of 14.24%. Thermo Fisher Scientific’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.62 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 12.33 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Tuesday, December 17th will be paid a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.83%.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 2,271 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $298.00, for a total value of $676,758.00. Following the completion of the transaction, the chief executive officer now owns 283,502 shares in the company, valued at approximately $84,483,596. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 47,729 shares of the company’s stock in a transaction on Friday, October 25th. The shares were sold at an average price of $295.88, for a total value of $14,122,056.52. Following the completion of the transaction, the chief executive officer now owns 328,960 shares of the company’s stock, valued at approximately $97,332,684.80. The disclosure for this sale can be found here. Insiders sold a total of 51,833 shares of company stock valued at $15,299,095 in the last 90 days. Corporate insiders own 0.45% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: What is the Moving Average Convergence Divergence (MACD) oscillator?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.